1558036-85-3Relevant articles and documents
Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning
Schnute, Mark E.,Benoit, Stephen E.,Buchler, Ingrid P.,Caspers, Nicole,Grapperhaus, Margaret L.,Han, Seungil,Hotchandani, Rajeev,Huang, Nelson,Hughes, Robert O.,Juba, Brian M.,Kim, Kyung-Hee,Liu, Erica,McCarthy, Erin,Messing, Dean,Miyashiro, Joy S.,Mohan, Shashi,O'Connell, Thomas N.,Ohren, Jeffrey F.,Parikh, Mihir D.,Schmidt, Michelle,Selness, Shaun R.,Springer, John R.,Thanabal, Venkataraman,Trujillo, John I.,Walker, Daniel P.,Wan, Zhao-Kui,Withka, Jane M.,Wittwer, Arthur J.,Wood, Nancy L.,Xing, Li,Zapf, Christoph W.,Douhan, John
, p. 80 - 85 (2019/01/15)
Potent covalent inhibitors of Bruton's tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible-covalent inhibitors provided the highest combined BTK potency and EGFR selectivity. The cyanamide covalent mechanism with BTK was confirmed through enzyme kinetic, NMR, MS, and X-ray crystallographic studies. The lead cyanamide-based inhibitors demonstrated excellent kinome selectivity and rat pharmacokinetic properties.
Protein Kinase Inhibitors and Uses Thereof
-
Paragraph 0127; 0143; 0144; 0145; 0146, (2015/02/05)
The invention is compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Paragraph 0412, (2014/06/23)
The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolites, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provided the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. Formula (IV)